1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359


Real-time Euronext Amsterdam  -  11:35 2022-08-12 am EDT
53.38 EUR   +0.76%
08/09GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
08/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 - Form 6-K
08/08Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galapagos increases share capital through subscription right exercises

06/20/2022 | 04:02pm EDT

Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Galapagos issued 80,290 new ordinary shares on 20 June 2022, for a total capital increase (including issuance premium) of EUR 1,459,506.60.

Pursuant to the subscription right exercise program for Galapagos’ executive committee, the members of the executive committee automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one executive committee member exercised 5,000 subscription rights.

In accordance with Belgian transparency legislation1, Galapagos also wishes to note that its total share capital currently amounts to EUR 355,533,029.01, the total number of securities conferring voting rights amounts to 65,728,511, which is also the total number of voting rights (the denominator), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as ‘warrants’) to subscribe to not yet issued securities conferring voting rights is (i) 9,060,766 subscription rights under several outstanding personnel subscription right plans, which equals 9,060,766 voting rights that may result from the exercise of those subscription rights, and (ii) 1 subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead (and its affiliated companies) to 29.9% of the actually issued and outstanding shares after the exercise of such subscription right. The foregoing excludes the 2,326,025 subscription rights of Subscription Right Plan 2022 BE, Subscription Right Plan 2022 RMV and Subscription Right Plan 2022 ROW, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com.



Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63



Marieke Vermeersch
Head of Corporate Communication
+32 479 490 603


Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

1Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (as amended from time to time).



All news about GALAPAGOS NV
08/09GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K
08/08GALAPAGOS : First key steps in pipeline rebuild and strong commercial progress in H1 2022 ..
08/08Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
08/08Galapagos receives transparency notification from FMR LLC
08/08Galapagos receives transparency notification from FMR LLC
08/08RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating
08/08GALAPAGOS NV : Crossing thresholds
08/05Galapagos Q2 Loss Narrows as Net Revenue Falls
08/05TRANSCRIPT : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
08/04First key steps in pipeline rebuild and strong commercial progress in H1 2022
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Sales 2022 528 M 541 M 541 M
Net income 2022 -153 M -157 M -157 M
Net cash 2022 3 538 M 3 628 M 3 628 M
P/E ratio 2022 1 091x
Yield 2022 -
Capitalization 3 509 M 3 597 M 3 597 M
EV / Sales 2022 -0,06x
EV / Sales 2023 0,52x
Nbr of Employees 1 305
Free-Float 73,7%
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 9
Last Close Price 53,38 €
Average target price 60,56 €
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV7.64%3 596
MODERNA, INC.-32.35%67 212
LONZA GROUP AG-23.32%46 073
IQVIA HOLDINGS INC.-14.23%45 135
SEAGEN INC.12.57%32 099